Profile data is unavailable for this security.
About the company
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
- Revenue in CHF (TTM)5.93m
- Net income in CHF-14.50m
- LocationNewron Pharmaceuticals SpAvia Ludovico Ariosto 21BRESSO 20091ItalyITA
- Phone+39 26103461
- Fax+39 261034654